Drug Profile
Zolpidem oral spray - Amherst Pharmaceuticals
Alternative Names: Zolpidem tartrate oro-mucosal spray - Amherst; ZolpimistLatest Information Update: 29 Nov 2022
Price :
$50
*
At a glance
- Originator NovaDel Pharma
- Developer Amherst Pharmaceuticals; Arovella Therapeutics; Aytu BioPharma; Teva Pharmaceuticals USA
- Class Acetamides; Hypnosedatives; Imidazoles; Pyridines; Sleep disorder therapies; Small molecules
- Mechanism of Action GABA A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Insomnia
- No development reported Sleep maintenance insomnia
Most Recent Events
- 22 Mar 2021 Neos Therapeutics has merged with Aytu BioScience to form Aytu BioPharma
- 30 Jul 2020 Teva Pharmaceuticals and Mitsubishi Tanabe Pharma plans to submit regulatory applications for approval in Insomnia in Singapore, South Korea, Brazil, Chile and Mexico
- 30 Jul 2020 Registered for Insomnia in Australia (Transmucosal)